User: Guest  Login
Title:

CD47-targeted cancer immunogene therapy: Secreted SIRPα-Fc fusion protein eradicates tumors by macrophage and NK cell activation.

Document type:
Article; Journal Article
Author(s):
Billerhart, Magdalena; Schönhofer, Monika; Schueffl, Hemma; Polzer, Wolfram; Pichler, Julia; Decker, Simon; Taschauer, Alexander; Maier, Julia; Anton, Martina; Eckmann, Sebastian; Blaschek, Manuel; Heffeter, Petra; Sami, Haider; Ogris, Manfred
Abstract:
CD47 protects healthy cells from macrophage attack by binding to signal regulatory protein α (SIRPα), while its upregulation in cancer prevents immune clearance. Systemic treatment with CD47 antibodies requires a weakened Fc-mediated effector function or lower CD47-binding affinity to prevent side effects. Our approach combines "the best of both worlds," i.e., maximized CD47 binding and full Fc-mediated immune activity, by exploiting gene therapy for paracrine release. We developed a plasmid vec...     »
Journal title abbreviation:
Mol Ther Oncolytics
Year:
2021
Journal volume:
23
Pages contribution:
192-204
Fulltext / DOI:
doi:10.1016/j.omto.2021.09.005
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/34729396
TUM Institution:
Institut für Experimentelle Onkologie und Therapieforschung; Roman Herzog Comprehensive Cancer Center
 BibTeX